Cempra, Inc

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases and intends to utilize its series of proprietary lead compounds such uses as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Merged with Melinta Therapeutics in 2017.

Select Venture Capital & Financial Partners

Aisling Capital Devon Park Bioventures Intersouth Partners Quaker Bioventures, Inc. Wistar Morris III

www.cempra.com